Oncology (all articles)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials.
15 Oct, 2021 | 02:07h | UTC
Commentary on Twitter
@OncoAlert Success of a monoclonal antibody when @ right target – 10 yr benefits of trastuzumab – #EBCTCG meta-analysis (N>13,000):
👉Impressive absolute and relative ~1/3 reduced deaths, ~1/3 recurrences
👉ER-: Recur⬇️ 11%
👉ER+: Recur⬇️ 8%@kevinpunie @prat_aleix @itsnot_pink https://t.co/O1WKcEEuGG— Nicole Kuderer (@NicoleKuderer) August 4, 2021
Systematic Review: Direct oral anticoagulants (DOACs) may be beneficial for people being treated for cancer who have no therapeutic or prophylactic indication for anticoagulation.
14 Oct, 2021 | 09:44h | UTC
Systematic Review: Music interventions may have beneficial effects on anxiety, depression, hope, pain, and fatigue in adults with cancer.
14 Oct, 2021 | 09:43h | UTC
RCT: Among patients with metastatic colorectal cancer, those randomized to systemic treatment alone had lower sixty-day mortality compared to those randomized to primary tumor resection followed by systemic treatment.
12 Oct, 2021 | 00:01h | UTCSixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Editorial: Primary Tumor Resection and Patients With Asymptomatic Colorectal Cancer and Nonresectable Metastases: Results of Recent Randomized Trials – JAMA Surgery (free for a limited period)
Commentary: Systemic Therapy Alone Bests Surgical Tx for Metastatic CRC – BreakingMed
Commentary on Twitter
Early mortality in patients with colorectal cancer and unresectable metastases randomized to primary tumor resection followed by systemic treatment is considerably higher than early mortality in patients randomized to systemic treatment only https://t.co/SyfYjmDU7i @DaveKruijssen
— JAMA Surgery (@JAMASurgery) October 11, 2021
Position statement on percutaneous ablation of non-small cell lung cancer and metastatic disease to the lungs.
8 Oct, 2021 | 10:12h | UTC
Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.
8 Oct, 2021 | 10:07h | UTC
Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents.
7 Oct, 2021 | 10:14h | UTC
Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.
6 Oct, 2021 | 10:09h | UTC
Commentary on Twitter (thread – click for more)
What were the unintended consequences of COVID lockdowns on cancer care?@CovidSurg study in @TheLancetOncol:
🔹Lockdowns independently associated with delayed treatment
🔹At median 5.3 months f/u, 1 in 7 pts had not had planned cancer surgery🆓https://t.co/UZe0euq5kg pic.twitter.com/4fPl6UEb9D
— Dmitri Nepogodiev (@dnepo) October 5, 2021
SILENCE Randomized Trial: In patients at the end of life, prophylactic subcutaneous scopolamine butylbromide reduces the occurrence of the death rattle (noisy breathing caused by mucus in the upper respiratory tract).
6 Oct, 2021 | 09:54h | UTCEffect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of LifeThe SILENCE Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide – JAMA (free for a limited period)
Author interview: Scopolamine Butylbromide for Preventing End-of-Life Death Rattle – JAMA
Commentary on Twitter
In a randomized clinical trial among patients near the end of life, prophylactic subcutaneous scopolamine butylbromide significantly reduced the occurrence of death rattle https://t.co/e6BDI5yirY pic.twitter.com/hHfhC2iYHh
— JAMA (@JAMA_current) October 5, 2021
The diagnosis and management of endocrine side effects of immune checkpoint inhibitors.
6 Oct, 2021 | 08:44h | UTCRelated: Review: Endocrine complications of immunotherapies
WHO prioritizes access to diabetes and cancer treatments in new Essential Medicines Lists.
3 Oct, 2021 | 22:46h | UTCNews Release: WHO prioritizes access to diabetes and cancer treatments in new Essential Medicines Lists – World Health Organization
Report: WHO model list of essential medicines – 22nd list, 2021 – World Health Organization
Commentary: For the first time, WHO committee recommends action on high-priced essential medicines – STAT
Commentary on Twitter (thread – click for more)
🆕 WHO 2021 Essential Medicines Lists have 20 new medicines for adults & 17 for children, incl. insulin analogues, new oral medicines for diabetes & medicines for cancer treatment https://t.co/LfWwHEZtuM pic.twitter.com/HMFOP8ioBf
— World Health Organization (WHO) (@WHO) October 1, 2021
Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?
3 Oct, 2021 | 22:33h | UTCOriginal article: Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE – Cochrane Library
Cohort Study: Women treated with radiation therapy for left-sided breast cancer had over twice the risk of subsequent coronary artery disease compared with women treated with radiation therapy for right-sided breast cancer.
1 Oct, 2021 | 10:21h | UTCCommentaries:
CAD in Young Women After Radiation Therapy for Breast Cancer – American College of Cardiology
Commentary on Twitter
According to a study from #JACCCardioOnc, women with left-sided breast cancer undergoing radiation therapy between 1985 and 2008 had over twice the risk of subsequent #cvCAD compared to women with right-sided breast cancer. Learn more here: https://t.co/5q9tToSSRp #CardioOnc
— American College of Cardiology (@ACCinTouch) September 22, 2021
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.
1 Oct, 2021 | 09:57h | UTC
Review: Recent Advances in the Management of Metastatic Prostate Cancer
1 Oct, 2021 | 09:55h | UTCRecent Advances in the Management of Metastatic Prostate Cancer – JCO Oncology Practice
RCT: Neurolytic splanchnic nerve block and pain relief, survival, and quality of life in unresectable pancreatic cancer.
30 Sep, 2021 | 10:16h | UTC
Commentary on Twitter
Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial https://t.co/xa9sPAdQu1 pic.twitter.com/gi74fdDSfl
— Anesthesiology journal (@_Anesthesiology) August 30, 2021
Gastrointestinal stromal tumors: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
30 Sep, 2021 | 10:11h | UTC
NCCN Guideline: Older Adult Oncology
30 Sep, 2021 | 09:59h | UTC
RCT: Overall survival benefit with Tebentafusp in metastatic uveal melanoma.
28 Sep, 2021 | 09:03h | UTC
Commentary on Twitter
Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. https://t.co/HnSdWItKIp pic.twitter.com/qu4huRn3Mu
— NEJM (@NEJM) September 27, 2021
Podcast: Neutropenic Fever.
28 Sep, 2021 | 08:52h | UTC#288 LIVE! Neutropenic Fever featuring Dr. Susan Seo – The Curbsiders
RCT: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.
26 Sep, 2021 | 21:43h | UTCCommentary: KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer – The ASCO Post
Clinical Review on the Management of Metastatic Renal Cell Carcinoma.
26 Sep, 2021 | 21:41h | UTCClinical Review on the Management of Metastatic Renal Cell Carcinoma – JCO Oncology Practice
M-A: Treatment options for progression or recurrence of glioblastoma.
26 Sep, 2021 | 21:34h | UTCSummary: Treatment options for people with recurrent and progressive glioblastoma – Cochrane Library
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
24 Sep, 2021 | 08:55h | UTCRelated:
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment (several resources on the subject)
Consensus Document: Evaluation and management of cancer patients presenting with acute cardiovascular disease—Part 1: acute coronary syndromes and acute pericardial diseases.
23 Sep, 2021 | 10:01h | UTCRelated:
Brazilian Cardio-oncology Guideline – 2020
Commentary on Twitter
📌Evaluation & Management of Cancer 👥presenting w/ Acute Coronary Syndromes & Acute Pericardial diseases. Consensus📝from #ACVC & the @escardio council of #CardioOncology#CardioEd #CardioTwitter #CardioOnc #EchoFirst pic.twitter.com/QSNOv7uFK7
— Diego Segura (@SeguraCardio) September 19, 2021